| Nov 21 |
Harrow’s ImprimisRx Subsidiary Receives $34.9 Million Unanimous Jury Verdict Award in ImprimisRx, LLC v. OSRX, Inc.
|
| Nov 20 |
Melt Pharmaceuticals Reports Positive Phase 3 Topline Efficacy Results for MELT-300, Its Lead Product Candidate for Opioid-Free, Sublingual Procedural Sedation in Patients Undergoing Cataract Surgery
|
| Nov 16 |
Harrow: Spotlight On IHEEZO
|
| Nov 15 |
Harrow Announces Participation in Upcoming Investor Conferences
|
| Nov 15 |
Harrow Inc (HROW) Q3 2024 Earnings Call Highlights: Record Revenue and Strategic Growth Amid ...
|
| Nov 14 |
Harrow, Inc. (HROW) Q3 2024 Earnings Call Transcript
|
| Nov 14 |
Harrow, Inc. 2024 Q3 - Results - Earnings Call Presentation
|
| Nov 14 |
Why DLocal Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
|
| Nov 13 |
Harrow stock plunges 20% on weaker-than-expected Q3 earnings
|
| Nov 13 |
Harrow Health Non-GAAP EPS of -$0.05 misses by $0.12, revenue of $49.26M misses by $3.55M
|
